Beyond GLP-1 headlines, the real question is which weight-loss path fits best now GPCR-based therapies are exciting because they may expand obesity care beyond injections and beyond the usual side-effect pattern. Most of…
Longer duration sounds appealing, but fit still matters more than a trend label Daxxify’s longer wear may be attractive for readers who want fewer touch-ups and more predictable maintenance. The hormone-sensitive angle is…
More selective estrogen therapy sounds promising, but the immediate need is still a safer current plan Designer estrogens remain investigational, so they belong to the pipeline rather than today’s treatment menu. The practical…
A cellular fat-loss strategy may be the future, but the better question is what helps now Mitochondrial uncouplers are drawing attention because they aim to increase energy expenditure without relying on stimulant pathways.…